Evidence map›Paper›PMID 37194253›Full record

ArticleJournal of psychopharmacology (Oxford, England)2023

Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.

Noah Chisamore, Kevork Danayan, Nelson B Rodrigues, Joshua D Di Vincenzo, Shakila Meshkat, Zoe Doyle, Rodrigo Mansur, Lee Phan, Farhan Fancy, Edmond Chau and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Rethinking the Treatment-Resistant Depression.Advances in experimental medicine and biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Noah ChisamoreMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.ORCID 0000-0003-3325-5854
Kevork DanayanMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-3764-9677
Nelson B RodriguesMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-8128-5612
Joshua D Di VincenzoMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Shakila MeshkatMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Zoe DoyleCanadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada.
Rodrigo MansurMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Lee PhanMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Farhan FancyMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-9638-6061
Edmond Chau
Aniqa TabassumMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Kevin KratiukCanadian Rapid Treatment Centre of Excellence, Mississauga, ON, Canada.
Anil ArekapudiMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Roger S McIntyreMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.
Joshua D RosenblatMood Disorders Psychopharmacology Unit, University Health Network, Toronto, ON, Canada.ORCID 0000-0002-4773-2191
University Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundKetamine is an emerging treatment for treatment-resistant depression (TRD) associated with rapid and robust improvements in depressive symptoms and suicidality. However, the efficacy and safety of ketamine in transitional age youth (TAY; age 18-25) populations remains understudied.

methodsIn this retrospective analysis, TAY patients (

resultsA significant main effect of infusions on reduction of total QIDS-SR16 (

conclusionKetamine was associated with comparable clinical benefits, safety, and tolerability in a TAY sample as compared to a matched GA TRD sample.

Indexed as

Depressive Disorder, Treatment-ResistantKetamineAdolescentAdultDepressionHumansInfusions, IntravenousMiddle AgedRetrospective StudiesYoung AdultKetamineDepressionketaminemajor depressive disordertransitional age youthtreatment-resistant depression

Identifiers

PMID37194253
PMCPMC10399094
OpenAlexW4376871046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.